Pair page
MOTS-c with Pancragen
Mechanism-tag overlap and published literature for MOTS-c and Pancragen, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
mitochondrial-derived-exercise-mimetic
khavinson-pancreatic-bioregulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying MOTS-c and Pancragen have published these mechanism-level observations. Not a co-administration recommendation.
MOTS-c is a mitochondrial-derived peptide that improves peripheral insulin sensitivity and muscle glucose uptake. Pancragen supports pancreatic β-cell function (insulin production); MOTS-c improves peripheral response to insulin. Mechanistically complementary within the metabolic optimization framework.
Quick facts
MOTS-c
Pancragen
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2022 | MOTS-c | Ramanjaneya M, Jerobin J, Bettahi I, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. PMID: 36233287. PMID 36233287 | human study |
| 2022 | MOTS-c | Yin X, Jing Y, Chen Q, et al. The intraocular expression of MOTS-c in patients with age-related cataracts: Correlation between MOTS-c and lens mitochondrial DNA levels. Clin Exp Ophthalmol. 2022;50(5):498-506. | human study |
| 2018 | MOTS-c | Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246. PMID 29983246 | mechanism / discovery |
| 2023 | MOTS-c | Kong BS, Lee C, Cho YM. Mitochondrial-encoded peptide MOTS-c, diabetes, and aging-related diseases. Diabetes Metab J. 2023;47(3):315-327. PMID: 36672073. PMID 36672073 | research article |
| 2021 | MOTS-c | Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. P… PMID 33473109 | research article |
| 2018 | MOTS-c | Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence. Rejuvenation Res. 2018;21(4):369-373. PMID: 30037300. PMID 30037300 | research article |
| 2015 | MOTS-c | Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459. DOI: 1… PMID 25738459 | research article |
| 2013 | MOTS-c | Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24(5):222-228. PMID: 23402768. PMID 23402768 | research article |
| 2021 | Pancragen | Khavinson V, Popovich I, Linkova N, Mironova E, Ilina A. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834146. PMID 34834146 | systematic review |
| 2020 | Pancragen | Khavinson VKh, Kuznik BI, Trofimova SV, Lin'kova NS. Cortexin and its short peptides AEDG and EDR modulate gene expression of proteins in pathogenesis of Alzheimer's disease. Biomed Khim. 2020. (Parallel framework evidence for the Khavinson short-peptide gene-expression paradigm… | mechanism / discovery |
| 2020 | Pancragen | Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Int J Mol Sci. 2020;21(2):609. PMID: 31963526. PMID 31963526 | mechanism / discovery |
| 2015 | Pancragen | Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic Mechanisms of Peptidergic Regulation of Gene Expression during Aging of Human Cells. Biochemistry (Mosc). 2015;80(3):310-322. PMID: 25761684. PMID 25761684 | mechanism / discovery |
| 2020 | Pancragen | Khavinson VK. Peptide regulation of ageing: 40 years of research. Adv Gerontol. 2020. (Retrospective review of the Khavinson peptide program; Pancragen placed in context.) | review |
| 2022 | Pancragen | Khavinson VK, Kuznik BI, Lin'kova NS, et al. Peptide Medicines: Past, Present, Future. Clin Med (Russian Journal). 2022;100(1):5-13. (Comprehensive framework review placing Pancragen in broader bioregulator context.) | bioregulator literature |
| 2022 | Pancragen | Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of aging: methodology and evidence. Bull Exp Biol Med. 2022. | bioregulator literature |
| 2020 | Pancragen | Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation, Proliferation, and Apoptosis. Adv Gerontol. 2020;10(2):98-106. | bioregulator literature |
| 2019 | Pancragen | Kolchina N, Khavinson V, Linkova N, Yakutseni P, Petukhov M, Morozova E, Ashapkin V. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Res. 2019;47(20):10553-10563. PMID: 31584079. PMID 31584079 | bioregulator literature |
| 2015 | Pancragen | Linkova NS, Drobintseva AO, Orlova OA, et al. Peptide regulation of beta-cell function during aging. Adv Gerontol. 2015;28(3):478-484. | bioregulator literature |
| 2010 | Pancragen | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997. PMID 19633997 | bioregulator literature |
| 2005 | Pancragen | Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger; Basel; 2005. (Monograph; framework reference for all Khavinson peptides including Pancragen.) | bioregulator literature |
Related pair pages
More research context
Frequently asked
Have MOTS-c and Pancragen been studied together?
Researchers have published mechanistic-level co-administration discussion of MOTS-c and Pancragen. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do MOTS-c and Pancragen share?
MOTS-c and Pancragen do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of MOTS-c and Pancragen?
MOTS-c: Not approved. Pancragen: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on MOTS-c and Pancragen?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the MOTS-c profile and the Pancragen profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026